Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Payables (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Payables over the past 15 years, most recently at $8.2 million for Q2 2025.

  • For Q2 2025, Payables fell 49.68% year-over-year to $8.2 million; the TTM value through May 2025 reached $8.2 million, down 49.68%, while the annual FY2025 figure was $8.2 million, 49.68% down from the prior year.
  • Payables for Q2 2025 was $8.2 million at Lifecore Biomedical, Inc. \De\, up from $7.4 million in the prior quarter.
  • Over five years, Payables peaked at $22.1 million in Q2 2023 and troughed at $7.4 million in Q1 2025.
  • A 5-year average of $13.3 million and a median of $13.3 million in 2022 define the central range for Payables.
  • Biggest five-year swings in Payables: tumbled 86.04% in 2021 and later soared 70.61% in 2023.
  • Year by year, Payables stood at $8.7 million in 2021, then soared by 53.68% to $13.3 million in 2022, then surged by 43.02% to $19.0 million in 2023, then fell by 21.32% to $15.0 million in 2024, then crashed by 45.08% to $8.2 million in 2025.
  • Business Quant data shows Payables for LFCR at $8.2 million in Q2 2025, $7.4 million in Q1 2025, and $15.0 million in Q4 2024.